Σφακιανάκης Αλέξανδρος
ΩτοΡινοΛαρυγγολόγος
Αναπαύσεως 5 Άγιος Νικόλαος
Κρήτη 72100
00302841026182
00306932607174
alsfakia@gmail.com

Αρχειοθήκη ιστολογίου

! # Ola via Alexandros G.Sfakianakis on Inoreader

Η λίστα ιστολογίων μου

Τρίτη 2 Απριλίου 2019

Taylor & Francis


 
 
 
Inhibition of PI3K pathway increases immune infiltrate in muscle-invasive bladder cancer
 
Inhibition of PI3K pathway increases immune infiltrate in muscle-invasive bladder cancer
Edith Borcoman, Philippe De La Rochere, Wilfrid Richer -OncoImmunology
 
" Although immune checkpoint inhibitors have shown improvement in survival in comparison to chemotherapy in urothelial bladder cancer, many patients ..." | Read Full Text >
 
 
 
 
Check out what else is new for you this week...
 
 
 
 
Increased bone marrow SUVmax on 18F-FDG PET is associated with higher pelvic treatment failure in patients with cervical cancer treated by chemoradiotherapy and brachytherapy
Romain-David Seban, Charlotte Robert, Laurent Dercle - OncoImmunology
 
" The aim of this study was to evaluate if bone marrow (BM) SUVmax measured on pre-treatment 18F-FDG PET/CT predicts the clinical outcome of locally advanced cervical cancer" | Read Full Text >
 
 
 
 
SpCas9-expression by tumor cells can cause T cell-dependent tumor rejection in immunocompetent mice
Reham Ajina, Danielle Zamalin, Annie Zuo - OncoImmunology
 
" The CRISPR/Cas9 system has recently emerged as a highly efficient modality in genetic engineering and has been widely considered for various therapeutic applications. Howev" | Read Full Text >
 
 
 
 
Efficacy and safety of immune checkpoint inhibitors in advanced gastric or gastroesophageal junction cancer: A systematic review and meta-analysis
Cong Chen, Fan Zhang, Ning Zhou - OncoImmunology
 
" Background : Immune checkpoint inhibitors (ICI) have shown promising prospects in gastroesophageal junction (G/GEJ) cancer immunotherapy, many clinical trials h" | Read Full Text >
 
 
 
 
Sub-Cutaneous Fat Mass measured on multislice computed tomography of pretreatment PET/CT is a prognostic factor of stage IV non-small cell lung cancer treated by nivolumab.
Geoffrey Popinat, Stéphanie Cousse, Lucas Goldfarb - OncoImmunology
 
" Introduction : Our aim was to explore the prognostic value of anthropometric parameters in patients treated with nivolumab for stage IV non-small cell lung canc" | Read Full Text >

Δεν υπάρχουν σχόλια:

Δημοσίευση σχολίου

Αρχειοθήκη ιστολογίου